Script: How Cultured Meat is Made

Text of the audio overview — read, annotate, or suggest edits via Hypothes.is

Note

This is the text of the process overview audio linked from this site. It was generated by AI (OpenAI GPT-4 + TTS-1-HD, May 2026), based on the content of the How Cultured Chicken is Made page and related materials. It has been reviewed by The Unjournal team and is generally accurate; however, it may state some things more definitively than we would ourselves, and it reflects the page content at a point in time.

To suggest corrections or flag inaccuracies: annotate this page via the Hypothes.is sidebar (click < on the right edge). To return to the main page: How Cultured Chicken is Made · Interactive Cost Model.

Cultivated meat — also called cell-based or cultured meat — is produced by growing animal cells in a controlled environment rather than raising and slaughtering animals. The basic idea is simple: take a small sample of cells from an animal, give them the right conditions to grow, and you end up with genuine animal muscle tissue, produced without the animal.

That’s the concept. The reality involves some sophisticated biology and engineering, and understanding it is essential for anyone thinking seriously about whether this technology can become commercially viable. This overview walks through the main steps of the production process and flags where costs enter the picture at each stage.

Where it starts: cells from an animal

Every batch of cultured meat traces back to a cell source. Cells are taken from a living animal via a small biopsy — typically a few milligrams of tissue causing minimal harm — or more commonly at scale, from tissue collected at slaughter. Either way, the goal is to isolate specific cell types: primarily muscle satellite cells, which are the stem cells that naturally repair muscle tissue in living animals.

The challenge is that these cells, in their natural state, will only divide a limited number of times before they stop. Primary cells have a biological clock — the Hayflick limit — of roughly fifty to eighty doublings before they senesce, meaning they stop dividing and eventually die. For a manufacturing process that needs to run continuously for years, that’s a fundamental problem.

The solution is cell immortalization — making cells capable of dividing indefinitely. This can happen in two ways. In some avian species, particularly chickens, a small fraction of cells spontaneously acquire random mutations that allow them to keep dividing. This is a rare event, but when it happens, you have a cell line that can be grown indefinitely without any intentional genetic modification — and that’s commercially valuable because it sidesteps the regulatory and consumer concerns associated with genetically modified organisms.

The other route is deliberate gene editing: introducing specific modifications that switch off the signals that normally stop cell division. This is more controllable and applicable to a wider range of species, but it comes with regulatory complexity and potential labeling requirements in some markets.

The cell bank: a frozen library

Once you have a cell line — whether spontaneously immortalized or gene-edited — you characterize it carefully and then freeze large quantities of it. This frozen inventory is called a cell bank.

Think of it like a master copy. Every vial is essentially identical, so every production batch starts from the same genetic starting point. In the pharmaceutical industry, cell banking is standard practice for exactly this reason: consistency and reproducibility depend on having a stable, well-characterized cell source.

In cultivated meat, cell banking is a one-time setup cost. Once established, the same cell bank can support years of production. The cost per kilogram of output is negligible — well under a dollar — because one vial thawed and expanded produces enormous quantities of cells before a bank even needs refreshing.

The seed train: scaling up from a vial

A typical production batch starts with a frozen vial containing perhaps a million cells. The production bioreactor might hold ten to twenty thousand liters. Getting from one to the other requires a series of progressively larger vessels — this is called the seed train.

You start with small flasks, move to small bioreactors, then larger ones, roughly multiplying the volume by a factor of ten at each step. It takes perhaps ten to fifteen days to go from a thawed vial to enough cells to inoculate a production-scale reactor. The seed train typically represents only a few percent of total production cost.

The production bioreactor: where the cost picture is shaped

The large production bioreactor is where most of the cost decisions are made. These are industrial-scale stirred tanks — engineered to keep cells alive, growing, and productive at densities that make commercial production economically viable.

The choice of process mode is one of the most consequential decisions in production design. Fed-batch mode adds nutrients incrementally during the run and harvests everything at the end — simpler and cheaper to operate, but limited to lower cell densities of roughly thirty to fifty grams per liter. Perfusion mode continuously flows fresh media through the reactor while retaining cells, achieving densities three to five times higher but at greater equipment complexity. A third approach, continuous mode, simultaneously feeds fresh media and harvests cells to maintain a steady state, potentially reaching even higher effective densities.

Cell density matters enormously for economics: at low density, you consume a lot of expensive media to produce a small amount of cells. At high density, each liter of media produces far more output. However, density and media cost are not independent — richer (and more expensive) media formulations are often needed to sustain very high cell densities, particularly in fed-batch systems where cells deplete the available nutrients.

Cell culture media: the nutrient broth

The liquid that cells grow in — the culture media — is one of the largest cost components. It has to provide everything cells need: amino acids to build proteins, glucose for energy, vitamins, minerals, buffering agents, and signalling molecules.

Expensive purified amino acids are a major cost driver. Hydrolysates — protein-breakdown products from yeast or plant sources — might substitute for them at a fraction of the cost, and there’s real industry momentum in that direction. Whether hydrolysate substitution works consistently at production scale is one of the key empirical questions this workshop aims to address.

Growth factors: the most uncertain cost driver

Beyond the basal nutrients, cells also need growth factors: small signalling proteins that tell them to keep dividing. At research scale, these proteins cost tens of thousands of dollars per gram, because they’re produced in tiny quantities for pharmaceutical research. Commercial cultivated meat would need them in vastly larger quantities.

There are several credible paths to much lower prices: precision fermentation using microbes; transgenic plants as a production platform; engineering cell lines to produce their own growth factors; or small molecules that activate the same receptors without using proteins. Any one of these working at scale would transform the cost picture.

Harvest and what comes next

When the production run is complete, cells are separated from the spent media — typically by centrifugation or filtration. What’s left is wet cell biomass: actual animal muscle tissue, typically seventy to eighty percent water by weight.

For unstructured products — minced meat, nuggets, hybrid products — this biomass can go relatively directly into processing. For structured products requiring whole-cut texture, additional scaffolding and texturization steps are needed.

The cost picture

At current small-scale production, cultivated meat is expensive — costs of hundreds of dollars per kilogram are typical. The path to commercial competitiveness runs through achieving high cell densities, securing cheap media and growth factors, and building at scales where capital costs spread thinly across large outputs. Whether that path can be traversed, and on what timeline, is what our cost model explores. See the interactive dashboard to explore the quantitative picture, and the beliefs form to share your expert views.

--- title: "Script: How Cultured Meat is Made" subtitle: "Text of the audio overview — read, annotate, or suggest edits via Hypothes.is" format: html: include-after-body: text: | <script src="https://hypothes.is/embed.js" async></script> --- ::: {.callout-note} This is the text of the **process overview audio** linked from this site. It was generated by AI (OpenAI GPT-4 + TTS-1-HD, May 2026), based on the content of the [How Cultured Chicken is Made](learn.qmd) page and related materials. It has been reviewed by The Unjournal team and is generally accurate; however, it may state some things more definitively than we would ourselves, and it reflects the page content at a point in time. **To suggest corrections or flag inaccuracies:** annotate this page via the Hypothes.is sidebar (click `<` on the right edge). To return to the main page: [How Cultured Chicken is Made](learn.qmd) · [Interactive Cost Model](index.qmd). ::: --- Cultivated meat — also called cell-based or cultured meat — is produced by growing animal cells in a controlled environment rather than raising and slaughtering animals. The basic idea is simple: take a small sample of cells from an animal, give them the right conditions to grow, and you end up with genuine animal muscle tissue, produced without the animal. That's the concept. The reality involves some sophisticated biology and engineering, and understanding it is essential for anyone thinking seriously about whether this technology can become commercially viable. This overview walks through the main steps of the production process and flags where costs enter the picture at each stage. --- **Where it starts: cells from an animal** Every batch of cultured meat traces back to a cell source. Cells are taken from a living animal via a small biopsy — typically a few milligrams of tissue causing minimal harm — or more commonly at scale, from tissue collected at slaughter. Either way, the goal is to isolate specific cell types: primarily muscle satellite cells, which are the stem cells that naturally repair muscle tissue in living animals. The challenge is that these cells, in their natural state, will only divide a limited number of times before they stop. Primary cells have a biological clock — the Hayflick limit — of roughly fifty to eighty doublings before they senesce, meaning they stop dividing and eventually die. For a manufacturing process that needs to run continuously for years, that's a fundamental problem. The solution is cell immortalization — making cells capable of dividing indefinitely. This can happen in two ways. In some avian species, particularly chickens, a small fraction of cells spontaneously acquire random mutations that allow them to keep dividing. This is a rare event, but when it happens, you have a cell line that can be grown indefinitely without any intentional genetic modification — and that's commercially valuable because it sidesteps the regulatory and consumer concerns associated with genetically modified organisms. The other route is deliberate gene editing: introducing specific modifications that switch off the signals that normally stop cell division. This is more controllable and applicable to a wider range of species, but it comes with regulatory complexity and potential labeling requirements in some markets. --- **The cell bank: a frozen library** Once you have a cell line — whether spontaneously immortalized or gene-edited — you characterize it carefully and then freeze large quantities of it. This frozen inventory is called a cell bank. Think of it like a master copy. Every vial is essentially identical, so every production batch starts from the same genetic starting point. In the pharmaceutical industry, cell banking is standard practice for exactly this reason: consistency and reproducibility depend on having a stable, well-characterized cell source. In cultivated meat, cell banking is a one-time setup cost. Once established, the same cell bank can support years of production. The cost per kilogram of output is negligible — well under a dollar — because one vial thawed and expanded produces enormous quantities of cells before a bank even needs refreshing. --- **The seed train: scaling up from a vial** A typical production batch starts with a frozen vial containing perhaps a million cells. The production bioreactor might hold ten to twenty thousand liters. Getting from one to the other requires a series of progressively larger vessels — this is called the seed train. You start with small flasks, move to small bioreactors, then larger ones, roughly multiplying the volume by a factor of ten at each step. It takes perhaps ten to fifteen days to go from a thawed vial to enough cells to inoculate a production-scale reactor. The seed train typically represents only a few percent of total production cost. --- **The production bioreactor: where the cost picture is shaped** The large production bioreactor is where most of the cost decisions are made. These are industrial-scale stirred tanks — engineered to keep cells alive, growing, and productive at densities that make commercial production economically viable. The choice of process mode is one of the most consequential decisions in production design. Fed-batch mode adds nutrients incrementally during the run and harvests everything at the end — simpler and cheaper to operate, but limited to lower cell densities of roughly thirty to fifty grams per liter. Perfusion mode continuously flows fresh media through the reactor while retaining cells, achieving densities three to five times higher but at greater equipment complexity. A third approach, continuous mode, simultaneously feeds fresh media and harvests cells to maintain a steady state, potentially reaching even higher effective densities. Cell density matters enormously for economics: at low density, you consume a lot of expensive media to produce a small amount of cells. At high density, each liter of media produces far more output. However, density and media cost are not independent — richer (and more expensive) media formulations are often needed to sustain very high cell densities, particularly in fed-batch systems where cells deplete the available nutrients. --- **Cell culture media: the nutrient broth** The liquid that cells grow in — the culture media — is one of the largest cost components. It has to provide everything cells need: amino acids to build proteins, glucose for energy, vitamins, minerals, buffering agents, and signalling molecules. Expensive purified amino acids are a major cost driver. Hydrolysates — protein-breakdown products from yeast or plant sources — might substitute for them at a fraction of the cost, and there's real industry momentum in that direction. Whether hydrolysate substitution works consistently at production scale is one of the key empirical questions this workshop aims to address. --- **Growth factors: the most uncertain cost driver** Beyond the basal nutrients, cells also need growth factors: small signalling proteins that tell them to keep dividing. At research scale, these proteins cost tens of thousands of dollars per gram, because they're produced in tiny quantities for pharmaceutical research. Commercial cultivated meat would need them in vastly larger quantities. There are several credible paths to much lower prices: precision fermentation using microbes; transgenic plants as a production platform; engineering cell lines to produce their own growth factors; or small molecules that activate the same receptors without using proteins. Any one of these working at scale would transform the cost picture. --- **Harvest and what comes next** When the production run is complete, cells are separated from the spent media — typically by centrifugation or filtration. What's left is wet cell biomass: actual animal muscle tissue, typically seventy to eighty percent water by weight. For unstructured products — minced meat, nuggets, hybrid products — this biomass can go relatively directly into processing. For structured products requiring whole-cut texture, additional scaffolding and texturization steps are needed. --- **The cost picture** At current small-scale production, cultivated meat is expensive — costs of hundreds of dollars per kilogram are typical. The path to commercial competitiveness runs through achieving high cell densities, securing cheap media and growth factors, and building at scales where capital costs spread thinly across large outputs. Whether that path can be traversed, and on what timeline, is what our cost model explores. See the [interactive dashboard](index.qmd) to explore the quantitative picture, and the [beliefs form](https://uj-cm-workshop.netlify.app/beliefs.html) to share your expert views.